XML 26 R15.htm IDEA: XBRL DOCUMENT v3.25.2
Goodwill and other intangible assets
 6 Months Ended
Jun. 29, 2025
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and other intangible assets Goodwill and other intangible assets
The following table provides information relating to changes in the carrying amount of goodwill by reportable operating segment for the six months ended June 29, 2025:
 AmericasEMEAAsiaTotal
December 31, 2024$1,932,769 $465,489 $234,056 $2,632,314 
Currency translation adjustment2,442 47,559 11,737 61,738 
June 29, 2025$1,935,211 $513,048 $245,793 $2,694,052 
Our Interventional Urology North America reporting unit is at risk for future goodwill impairment charges, which could be material, if there is a deterioration in general economic, market or business conditions or significant unfavorable changes in our forecasted current or long-term revenue growth rates, operating margins and/or discount rate. As of June 29, 2025, the carrying value of goodwill related to the Interventional Urology North America reporting unit was $403.9 million.
The gross carrying amount of, and accumulated amortization relating to, intangible assets as of June 29, 2025 and December 31, 2024 were as follows:
 Gross Carrying AmountAccumulated Amortization
 June 29, 2025December 31, 2024June 29, 2025December 31, 2024
Customer relationships$1,364,375 $1,354,087 $(659,017)$(620,619)
In-process research and development23,666 23,666 — — 
Intellectual property1,875,207 1,870,407 (922,037)(863,066)
Distribution rights18,766 23,004 (18,673)(22,524)
Trade names608,775 603,202 (106,750)(99,443)
Non-compete agreements21,937 21,894 (21,937)(21,894)
 
$3,912,726 $3,896,260 $(1,728,414)$(1,627,546)
We test the recoverability of long-lived assets whenever events or circumstances indicate the carrying value of an asset may not be recoverable. As of March 30, 2025, we identified indicators of a potential impairment related to the long-lived assets associated with our Titan SGS asset group, which primarily consists of intangible assets. The indicators of a potential impairment primarily arose from lower than expected sales of our Titan SGS product line and anticipated continuing reduced demand for bariatric surgery procedures in future periods driven by the growing adoption of GLP-1 products. We performed a recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates. We concluded that the undiscounted cash flows of the Titan SGS product line exceeded the carrying value of the related assets by approximately 10%. Accordingly, no impairment was recognized during the three or six months ended June 29, 2025 related to the Titan SGS asset group. If actual future revenues are lower than forecasted, it may result in future impairment charges, which could be material. The carrying value of the intangible assets as of June 29, 2025 was $127.5 million.